eagle-i University of Hawaii at ManoaUniversity of Hawaii at Manoa
See it in Search
This page is a preview of the following resource. Continue onto eagle-i search using the button on the right to see the full record.

Phase II Pilot Trial of Bortezomib (PS-341, Velcade, IND #58,443) in Combination With Intensive Re-Induction Therapy for Children With Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)

eagle-i ID


Resource Type

  1. Clinical trial


  1. ClinicalTrials.gov url
  2. Intervention
  3. Intervention
  4. Intervention
  5. Intervention
  6. Intervention
  7. Intervention
    Doxorubicin hydrochloride
  8. Intervention
    Etoposide phosphate
  9. Intervention
    Leucovorin calcium
  10. Intervention
  11. Intervention
  12. Intervention
  13. Intervention
    Therapeutic hydrocortisone
  14. Intervention
    Vincristine sulfate
  15. Resource Description
    "This phase II trial is studying the side effects of giving bortezomib together with combination chemotherapy and to see how well it works in treating young patients with relapsed acute lymphoblastic leukemia or lymphoblastic lymphoma."
  16. Additional Name
    Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
  17. Contact
    Berenberg, Jeffrey
  18. PI
    Wilkinson, Robert, M.D.
  19. Topic
    lymphoblastic leukemia
  20. Study Population
    Males and females aged 1-31 years old without optic nerve or retina involvement, Down syndrome, Fanconi anemia, Kostmann syndrome, Shwachman syndrome, or other bone marrow failure syndrome, no previous bortezomib, and at least 2 weeks since cytotoxic therapy and at least 4 months since stem cell transplant.
  21. Website(s)
  22. Funded by
    Children's Oncology Group
  23. Phase
    Phase 2 clinical trial
  24. Performed by
    Clinical Protocol & Data Management Shared Resource
Provenance Metadata About This Resource Record
Copyright © 2016 by the President and Fellows of Harvard College
The eagle-i Consortium is supported by NIH Grant #5U24RR029825-02 / Copyright 2016